港股午評：恒指大跌1.38%失守萬九關口 科技股、金融股走低
格隆匯5月23日丨經歷連翻上升的港股迎來明顯的回調行情，上午盤三大指數集體下挫，恒指跌1.38%失守萬九關口，國指跌1.45%，二者均錄得3連跌行情，恒生科技指數一度跌至2.35%，午間最終收跌1.68%。
盤面上，大型科技股、大金融股、中字頭股等權重皆表現低迷，阿里巴巴跌3.67%，京東跌近3%，中國銀行、中國太平、中金公司、中國建材等行業龍頭盡數下跌；金銀價格大幅回撤，黃金股、銅業股等有色金屬股跌幅明顯，山東黃金、五礦資源、中國鋁業紛紛下跌；昨日回暖的汽車股再度走低，重型機械股、半導體股、內房股與物管股等齊跌。 另一方面，短視頻概念股部分逆勢上升，快手績後一度升超4%，煤炭股、家電股少部分上升，權重股兗礦能源升超2%。
板塊方面
金銀價格大幅下挫，相關概念股走低。因美國聯邦公開市場委員會(FOMC)會議紀要措辭鷹派，打擊降息希望，黃金、白銀價格大幅下挫。繼昨日收跌1.75%後，倫敦金現今日盤中繼續下跌，一度跌至2366.3美元，為連續第三日回調。繼昨日收跌3.74%後，倫敦銀現今日再度下跌，一度跌超1%至30.23美元。
昨日回暖的汽車股再度下跌。美東時間5月22日清晨(北京時間5月22日傍晚)，美國貿易代表辦公室（USTR）公佈了對華新一輪301關税的草擬細則，將此前公佈的擬加徵關税的產品大類進一步細化到具體的產品名稱及海關編號，其中，鋼鋁、電動汽車和電動汽車鋰電池等產品的關税加徵將在8月1日生效。
個股方面
和鉑醫藥逆勢升超16%創逾2個月新高，與阿斯利康就單克隆抗體項目達成許可協議。消息面上，和鉑醫藥全資子公司諾納生物今日宣佈，與阿斯利康就臨牀前單克隆抗體項目達成許可協議，加速腫瘤靶向療法的開發。 根據協議，諾納生物在交易完成後將獲得1900萬美元首付款，並有權獲得1000萬美元可預期的近期里程碑付款，以及高達5.75億美元開發、監管及商業里程碑付款和基於淨銷售額的分級特許權使用費。此外，如果阿斯利康行使選擇權，諾納生物將進一步獲得相關付款。
網易跌5%，即將公佈業績。網易即將於5月23日美股盤前公佈業績。機構預計網易2024年一季度實現營收267.86億元，同比增加6.95%；每股收益12.13元，同比增加17.0%。
萬國數據大跌超12%，Q1業績遜預期。萬國數據公佈財報顯示，第一季度，淨收入26.27億元，同比增加9.1%，略低於分析師預期的26.7億元；第一季度每ADS虧損1.96元，較去年同期的2.67元虧損收窄，分析師預期虧損1.87元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
